Skip to main content

Ryan Arthur F's Form 4 filing

Regeneron Pharmaceuticals, Inc. (REGN) · filed Nov 3, 2021

Accession no.
0001883850-21-000007
Filed
Nov 3, 2021
Trade date
Nov 1, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 10 non-derivative transactions. Open-market sales total $64.3K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ryan Arthur FCIK 0001187443Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 1, 2021Common StockSSaleDisposed−6$638.62F2−$3,831.7223,185Direct
Nov 1, 2021Common StockSSaleDisposed−11$639.52F3−$7,034.7223,174Direct
Nov 1, 2021Common StockSSaleDisposed−17$640.08F4−$10,881.3623,157Direct
Nov 1, 2021Common StockSSaleDisposed−19$641.52F5−$12,188.8823,138Direct
Nov 1, 2021Common StockSSaleDisposed−9$642.28F6−$5,780.5223,129Direct
Nov 1, 2021Common StockSSaleDisposed−1$643.82−$643.8223,128Direct
Nov 1, 2021Common StockSSaleDisposed−9$644.62F7−$5,801.5823,119Direct
Nov 1, 2021Common StockSSaleDisposed−15$645.41F8−$9,681.1523,104Direct
Nov 1, 2021Common StockSSaleDisposed−5$646.37F9−$3,231.8523,099Direct
Nov 1, 2021Common StockSSaleDisposed−8$647.00−$5,17623,091Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents volume-weighted average price of sales of 6 shares of Company stock on November 1, 2021 at prices ranging from $638.57 to $638.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents volume-weighted average price of sales of 11 shares of Company stock on November 1, 2021 at prices ranging from $639.17 to $639.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

Represents volume-weighted average price of sales of 17 shares of Company stock on November 1, 2021 at prices ranging from $640.00 to $640.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F5

Represents volume-weighted average price of sales of 19 shares of Company stock on November 1, 2021 at prices ranging from $641.11 to $641.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F6

Represents volume-weighted average price of sales of 9 shares of Company stock on November 1, 2021 at prices ranging from $642.00 to $642.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F7

Represents volume-weighted average price of sales of 9 shares of Company stock on November 1, 2021 at prices ranging from $644.21 to $644.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F8

Represents volume-weighted average price of sales of 15 shares of Company stock on November 1, 2021 at prices ranging from $645.01 to $645.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

F9

Represents volume-weighted average price of sales of 5 shares of Company stock on November 1, 2021 at prices ranging from $646.00 to $646.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2021 at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)